enza B-virus and parainfluenza virus are less common but can contribute to increased morbidity and mortality. 2-9 A mortality rate of up to 78% has been reported for RSV Treatment with ribavirin was instituted in 12 allogeneic and one autologous bone marrow transplant (BMT) infection and pneumonia in BMT recipients.
Ribavirin
(1-␤-d-ribofuranosyl-1,2-triazole-3-carboxrecipients with proven respiratory syncytial virus (RSV), influenza B virus or parainfluenza virus infecamide) is a synthetic nucleoside analogue with broad spectrum and in vivo activity against RNA and DNA viruses.
11-
tions. RSV was diagnosed in six cases, influenza B virus in four and parainfluenzavirus in three patients. Ribavi- 15 Currently, it is approved only as aerosol therapy in small children with severe RSV pneumonia, [16] [17] but it is also rin was given orally or intravenously (15-20 mg/kg/day in three divided doses) and in nine cases with the being used widely in various clinical trials in chronic hepatitis C and HIV infection. Its mechanism of action in RSV addition of ribavirin inhalations (6 g/day). Three patients required ventilator support. Three out of seven infection appears to be interference, at the translatory level, with the expression of viral mRNA and viral proteins. patients with pneumonia, including one patient with RSV who developed pulmonary infiltrates 10 days after
Other possible mechanisms include decrease of intracellular levels of deoxyguanosine triphosphate and thereby inhithe start of therapy, died despite treatment with ribavirin (two RSV, one influenza B). Multiple etiological bition of viral enzymes such as RNA polymerases which has been shown for influenza C 1 virus. 14 There are no agents were found in the fatal cases. The clinical condition improved in 10 of 13 patients during therapy. No reports concerning systemic use of ribavirin in viral respiratory tract infections in BMT patients. serious adverse effects of systemic ribavirin were noticed. Two patients had reversible signs of hemolysis but only one patient required more erythrocyte transMaterials and methods fusions than expected after BMT. Obstructive respiratory distress was often observed (6/9 patients receiving Demography ribavirin inhalation therapy), which resulted in discontinuation of aerosolized therapy in four cases. Time to During the period 1988-1994, treatment with ribavirin was engraftment (WBC Ͻ 0.2 × 10 9 /l) did not differ from instituted in 12 allogeneic and one autologous BMT other non-treated BMT patients. We conclude that ribapatients with proven viral respiratory tract infections. Six virin is well tolerated both orally and intravenously and were children (7 months to 10 years of age) and seven were it may, if instituted before development of hypoxia, adults (20-50 years of age). The indications for BMT were: reduce morbidity and mortality of RSV, influenza B and hematological malignancies (n = 11), malignant osteoparainfluenza in this group of patients. petrosis (n = 1) and Mb. San Filippo A (n = 1). At the time Keywords: RSV; influenza; parainfluenza; infection; of diagnosis of respiratory virus infection, the majority of ribavirin; bone marrow transplantation the patients (n = 11) were pancytopenic following BMT, while two patients were 257 and 383 days post-BMT, respectively and had chronic graft-versus-host-disease (GVHD) with ongoing immunosuppression (Table 1) . Infection, especially during the aplastic phase, is one of the Chest X-ray was performed in all cases at onset of respirmost serious complications after BMT. Patients with signs atory symptoms. Upper respiratory tract infection was of infection and respiratory symptoms with or without lung defined as lack of infiltration combined with normal arterial infiltrates, have an increased mortality risk. 1 Microbial diagnosis combined parenteral and aerosol administration of ribavirin. Nasopharynx aspirates (NphA) and/or bronchioalveolar lavages (BAL) were obtained in patients with respiratory tract symptoms.
Results
Clinical symptoms and signs Virology
The methods for viral diagnosis were antigen detection by Pulmonary infiltrates were found on chest X-ray in 7/13 cases while six patients had only upper respiratory tract virus antigen-specific mAb visualized by indirect immunofluorescence and virus cultures. RSV was found in six symptoms. Five patients (two parainfluenza, two RSV and one influenza B) had pneumonia before initiation of therapy cases, influenza B in four and parainfluenza virus (one type 2, one type 3 and one unclassified) in three patients. 2 PCR with ribavirin (three of these patients were aplastic at the time of pneumonia); in the other two cases, pneumonia assessment was also performed for Herpes viruses and adenovirus.
developed 5 and 10 days after therapy had been instituted, respectively. Three patients required mechanical ventilation. None of the six patients with upper respiratory tract Antimicrobial prophylaxis and treatment infection (URI) had engrafted at the time of diagnosis. In addition to ribavirin therapy all patients received broadAcyclovir was given for viral prophylaxis during the aplastic phase. Patients with fever and/or respiratory symptoms spectrum antibiotics. received antibiotics and in selected cases also anti-fungal therapy after microbial assessment.
Effects on clinical symptoms and outcome
The characteristics of patients included, administration Ribavirin therapy route of ribavirin and clinical outcome are outlined in Table  1 . None of the six patients with upper respiratory tract The licensed route of administration of ribairin (aerosol) was initially used (three patients with influenza B, 1988-infections died. Five of six improved within 6 days after institution of therapy and one after 30 days. 1989). Due to adverse respiratory events we chose additional or only systemic therapy in the following cases Nine of 11 patients who became infected during the aplastic phase survived (three pneumonias, six URI), while with viral respiratory tract infections. Ribavirin was administrated either orally or intravenously (15-20 mg/kg/day in one of two patients infected after engraftment died. This patient died, however, more than a month after the last three divided doses), in six cases in combination with aerosol (6 g/day continously, for 15-18 h/day or 2 g for 1-4 isolation of RSV. Four patients (two RSV, one influenza B and one h, 3 times daily, given by a small particle generator, 1-5 m particles). The three patients with influenza B virus parainfluenza) were only treated systemically. Three recovered, while one patient with RSV pneumonia died. The infection were treated with inhalations alone. In addition, patients requiring assisted ventilation were treated with latter did not tolerate aerosol therapy due to obstructive bronchiolitis prior to RSV infection and treatment with parainfluenza) which led to discontinuation of ribavirin therapy after 7 and 8 days of treatment, respectively. The ribavirin.
Ribavirin therapy was discontinued when the viral agent patient with influenza B needed a second course of ribavirin due to persistent respiratory tract symptoms and detectable could no longer be demonstrated by antigen detection or viral cultures or when the patient's condition improved. It virus. This patient required 32 erythrocyte transfusions during the first 30 days following BMT. However, neutrophil was reinstituted in two cases (one influenza B and one parainfluenza), following reappearance of symptoms and and platelet engraftment were not delayed (day +21).
Obstructive respiratory distress, increased cough, pleurvirus in nasopharynx specimens.
In two cases (one RSV, one influenza B), ribavirin was itic pain and/or nausea were observed in 6/9 cases treated with aerosolized ribavirin. The inhalations were discondiscontinued when the patients had improved although virus was persistently found in nasopharynx specimens at tinued, due to side-effects, in four of these cases. Therapy was continued, in three cases by systemic administration 38 and 50 days after the start of therapy, respectively. The other two patients who had pneumonia when ribavirin was only. Generally, the adult patients had more difficulties in tolerating inhalations compared to children. Patients who instituted, as well as one of two who developed pneumonia after the start of therapy, improved during therapy despite required ventilatory support showed no signs of obstruction when aerosolized ribavirin was given. the fact that two patients, both with parainfluenza, required ventilator support and were aplastic at the time of diagnosis. In addition, one patient with RSV-associated interstitial pneumonia who was not treated with ribavirin died. Discussion One patient with influenza B after engraftment survived without antiviral therapy.
Respiratory tract infections caused by viruses other than CMV are not often diagnosed in BMT patients, but several The three out of seven patients with pneumonia who died despite treatment with ribavirin (two RSV, one influenza reports indicate that respiratory viruses such as adenovirus, influenza A, B, parainfluenza and RSV can be the cause of B) are outlined below.
Patient No. 1, an 8-month-old girl was transplanted due interstitial pneumonia and/or fever of unknown origin in this group of patients. [20] [21] [22] Harrington et al 10 reported 78% to malignant ostoepetrosis. RSV infection and Staphylococcus aureus septicemia was diagnosed the day she mortality among BMT recipients with RSV infection who had developed pneumonia during an outbreak at the Fred received the bone marrow transplant. Antibiotics and aerosolized ribavirin were instituted the next day, and two days Hutchinson Cancer Research Center. Parainfluenza 3 and influenza B infections have been reported to be more serilater parenteral ribavirin was added. She became hypoxic 10 days after starting ribavirin and pulmonary X-ray ous and more often associated with distal spread through the respiratory tract. 2, 3, 5, 8 In contrast, infections with parainshowed bilateral pulmonary infiltrates. Bronchoscopy was performed and CMV was found in bronchoalveolar lavage fluenza 1, 2 or influenza A appear to be self-limiting. 2, 4, 9 It is important to keep in mind the risks of nosocomial (BAL). She died at day + 21 after BMT, despite ventilatory support and intensive care. Autopsy showed hemorrhagic spread of such infections, particularly during epidemic seasons. This risk seems to be highest for RSV and parainpneumonia.
Patient No. 2 was a 4-year-old girl with FHL, who fluenza, probably due to the high frequency of subclinical episodes among immunocompetent individuals such as received bone marrow from an unrelated donor. She developed obstructive bronchiolitis, aspergillosis, intermithealthcare workers. Specific diagnostic procedures with sensitive laboratory tent CMV viremia, and had had serious respiratory impairment for several months when RSV was detected in a nasomethods such as antigen detection by IF or viral cultures can be of clinical value since it is difficult to distinguish pharynx aspirate. She was treated with parenteral ribavirin for 9 days and after 4 days therapy with ribavirin, RSV viral infection from other etiological causes of febrile illness or respiratory tract symptoms by clinical criteria. could not longer be isolated. She died of progressive respiratory insufficiency, 25 days after the ribavirin had been disRibavirin (Virazole; ICN Pharmaceuticals, Costa Mesa, CA, USA) is a synthetic nucleoside analogue with broad continued but without new findings of RSV in the nasopharyngeal aspirate. Autopsy was not performed. spectrum and in vivo activity against RNA and DNA viruses. [11] [12] [13] [14] [15] [16] The most common adverse effect from sysPatient No 3 was a 26-year-old male who had undergone autologous BMT for AML. Influenza B was found in a temic administration is a reversible, mild anemia, due to hemolysis. 23 No other significant adverse effects have been nasopharynx specimen on day +10. Ribavirin aerosol therapy was instituted on day +32 when he developed pulmonreported. However, when administered as an aerosol it may cause bronchoconstriction, increased cough and nausea. 5 ary infiltrates, and influenza B could still be detected in BAL. However, treatment with ribavirin was discontinued Our data are few and heterogeneous with regard to viral etiology; therefore, conclusions should be drawn with cau-48 h later due to severe pleuritic pain. He died on day +38, without engraftment. Pericardial aspergillosis and bilateral tion. However, only three of 13 patients treated with ribavirin died. Two had developed hypoxic pneumonia before hemorrhagic pneumonia were found at autopsy.
therapy was instituted and in all three, other conditions or infections could have contributed to the fatal outcome. In Adverse effects addition, in one of these cases, death was not attributable to the RSV infection since the virus was not isolated for Slightly elevated s-bilirubin levels were noticed (50-60 mol/l) in two cases (one influenza B and one more than a month prior to her death. Furthermore, only phase. Mortality among our patients was low compared 244-247. with previous reports in untreated cases. 2, 3, [8] [9] [10] In addition,
